Navigation Links
U.S. FDA Approves Requip(R) XL(TM), the First and Only Oral Once-Daily Non-Ergot Dopamine Agonist for Parkinson's Disease
Date:6/13/2008

nausea (11 percent vs. 4 percent), dizziness (8 percent vs. 3 percent), hallucination (7 percent vs. 3 percent), somnolence (7 percent vs. 4 percent), abdominal pain/discomfort (6 percent vs. 3 percent) and orthostatic hypotension (5 percent vs. 1 percent).

A Progressively Disabling Disease

Parkinson's disease is a chronic, progressive, and often disabling neurological condition that eventually impairs the body's ability to move and balance. Researchers have determined that Parkinson's disease involves the degeneration of the cells in one of the brain areas responsible for motor control. Patients with Parkinson's disease experience a reduction in dopamine, a key chemical in the brain that communicates messages about movement, resulting in the symptoms of Parkinson's disease. These symptoms include tremor (involuntary shaking), rigidity (stiffness), akinesia (lack of movement or loss of spontaneous movement), bradykinesia (slower-than-normal voluntary movements), and problems with walking, balance and posture.

More than one million people in the United States have Parkinson's disease. The average age of onset of Parkinson's disease is about 60 years, but the disease can develop at an earlier age.

About Requip XL

Requip XL Tablets are indicated in the U.S. for the treatment of the signs and symptoms of idiopathic Parkinson's disease and are administered once daily. Prescription Requip XL is not for everyone. Requip XL may cause patients to fall asleep or feel very sleepy during normal activities such as driving; or to faint or feel dizzy, nauseated, or sweaty when they stand up. Patients should tell their doctor if they experience these effects or the following problems, or if they drink alcohol or are taking other medicines that make them drowsy. Side effects may include nausea, dizziness, drowsiness or sleepiness, headache, and sudden uncontrolled movements (dyskinesia). Increase or decrease in blood pressure and heart rate may oc
'/>"/>

SOURCE GlaxoSmithKline
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. EPA Approves XDS-CALUX(R) as Alternate Dioxin Test Method 4435
2. FDA Approves HIFU Clinical Trial for Recurrent Prostate Cancer
3. U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older
4. U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) for the Acute Treatment of Manic and Mixed Episodes Associated With Bipolar I Disorder in Pediatric Patients (10 to 17 Years of Age)
5. UM Maryland Industrial Partnerships Program Approves 18 Collaborative Research Projects, Worth $4.4 Million, Between University Faculty, State Technology Companies
6. FDA Approves XYZAL(R) (levocetirizine dihydrochloride) Oral Solution for the Relief of Seasonal and Year Round Allergies and Chronic Idiopathic Urticaria
7. FDA Approves MiddleBrooks Amoxicillin PULSYS for Pharyngitis/Tonsillitis in Adolescents and Adults
8. European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection
9. FDA Approves Cymbalta(R) for Maintenance Treatment of Major Depressive Disorder
10. Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV
11. FDA Approves Lillys Osteoporosis Drug EVISTA(R) (raloxifene HCl) to Reduce The Risk of Invasive Breast Cancer in Two Populations of Postmenopausal Women
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... SAN DIEGO , July 30, 2015  Arena ... will host a conference call and webcast at 5:00 ... August 5, 2015, to discuss second quarter 2015 financial ... its financial results after the NASDAQ Global Select Market ... be accessed by dialing 877.643.7155 for domestic callers and ...
(Date:7/30/2015)... EnteroMedics Inc. (NASDAQ: ETRM ), the ... obesity, metabolic diseases and other gastrointestinal disorders, today announced ... August 6, 2015, at 11:00 AM Eastern Time to ... 30, 2015, and to provide an update on the ... the Maestro® System. Conference Call Details ...
(Date:7/30/2015)... VANCOUVER, Washington , July 30, 2015 ... diagnostics market 2015 research reports analyzing tumor ... well as providing forecasts for the global ... The Global Cancer Diagnostics Industry (Tumor Biomarker ... spread across 207 pages, talking about 9 ...
Breaking Medicine Technology:Arena Pharmaceuticals to Host Second Quarter 2015 Financial Results and Corporate Update Conference Call and Webcast on Wednesday, August 5 2Arena Pharmaceuticals to Host Second Quarter 2015 Financial Results and Corporate Update Conference Call and Webcast on Wednesday, August 5 3Arena Pharmaceuticals to Host Second Quarter 2015 Financial Results and Corporate Update Conference Call and Webcast on Wednesday, August 5 4EnteroMedics to Host Second Quarter 2015 Financial Results and Company Update Conference Call 2EnteroMedics to Host Second Quarter 2015 Financial Results and Company Update Conference Call 3Cancer Diagnostics Market to see 12% CAGR to 2020: Analysis of Tumor Biomarker Tests, Imaging, Endoscopy, Biopsy and More in New Research Reports 2Cancer Diagnostics Market to see 12% CAGR to 2020: Analysis of Tumor Biomarker Tests, Imaging, Endoscopy, Biopsy and More in New Research Reports 3Cancer Diagnostics Market to see 12% CAGR to 2020: Analysis of Tumor Biomarker Tests, Imaging, Endoscopy, Biopsy and More in New Research Reports 4Cancer Diagnostics Market to see 12% CAGR to 2020: Analysis of Tumor Biomarker Tests, Imaging, Endoscopy, Biopsy and More in New Research Reports 5Cancer Diagnostics Market to see 12% CAGR to 2020: Analysis of Tumor Biomarker Tests, Imaging, Endoscopy, Biopsy and More in New Research Reports 6
...  MedAssurant, Inc., a leading provider of data-driven ... IPA (HCPIPA), one of the largest physician-owned ... has selected MedAssurant,s Prospective Advantage® and Capitated ... gaps in care and quality to improve ...
... knowing how to take a child,s temperature the correct way ... accuracy of results can be a guessing game.  The new ... Behind Ear Thermometer ... confidence to parents and peace of mind.  Using patented technology, ...
Cached Medicine Technology:Healthcare Partners, IPA, Implements MedAssurant's Innovative, Data-Driven Solutions 2Healthcare Partners, IPA, Implements MedAssurant's Innovative, Data-Driven Solutions 3Behind The Ear -- A New Site To Measure for Fever 2Behind The Ear -- A New Site To Measure for Fever 3
(Date:7/30/2015)... ... July 30, 2015 , ... In a meaningful ritual ... Serenity Palms Drug Addiction Treatment Center have created an addiction graveyard. Sharing this with ... its most beloved residents, Rocky Hudson . Hudson (1945-2015) fell in love with ...
(Date:7/30/2015)... , ... July 30, 2015 , ... ... program at ATA’s 21st Annual Meeting and Tradeshow focused exclusively on telemedicine, telehealth ... 300 cutting-edge health care technology vendors, will take place May 14-17, 2016 in ...
(Date:7/30/2015)... ... ... " DevExpress ” was featured on NewsWatch as part ... large businesses making an impact in their industry. Susan Bridges, a reporter for ... how DevExpress has provided software development tools that have helped app developers build ...
(Date:7/30/2015)... ... July 30, 2015 , ... ... announce its position as one of Medicare’s top-rated care centers. The video ... the CMS rating system, which monitors health inspections, staffing, and quality measures. ...
(Date:7/30/2015)... ... July 30, 2015 , ... OncLive®’s extensive roster ... Jonsson Comprehensive Cancer Center (JCCC) mutually agreed to collaborate on projects that ... and marketing groups will help spread the news about the center’s leading-edge cancer ...
Breaking Medicine News(10 mins):Health News:Serenity Palms Honors Rocky Hudson, an Advocate of AA and a Beloved Resident of Palm Springs 2Health News:Serenity Palms Honors Rocky Hudson, an Advocate of AA and a Beloved Resident of Palm Springs 3Health News:Presentation Proposals for ATA 2016 are Now Being Accepted Online at ATA2016.com 2Health News:Presentation Proposals for ATA 2016 are Now Being Accepted Online at ATA2016.com 3Health News:Software to Develop High-Performance Data-Driven Apps was Featured on NewsWatch Television 2Health News:Beachside Nursing Center Releases New Video 2Health News:UCLA Jonsson Comprehensive Cancer Center Teams with OncLive® as a Strategic Alliance Partner 2Health News:UCLA Jonsson Comprehensive Cancer Center Teams with OncLive® as a Strategic Alliance Partner 3Health News:UCLA Jonsson Comprehensive Cancer Center Teams with OncLive® as a Strategic Alliance Partner 4
... ANN ARBOR, Mich. Having an egg allergy is ... vaccination. According to new recommendations by the American ... a history of suspected egg allergy should first be ... and diagnosis but can probably receive the vaccination. Matthew ...
... News) -- Very young children are extraordinarily trusting of what ... the contrary, finds a new study. In what may ... found that 3-year-olds placed more trust in information they are ... this study, an adult showed children a red and a ...
... Cancer Institute has awarded a $4.37 million grant to ... Center, to advance a recent scientific laboratory discovery into ... issued under the American Recovery and Reinvestment Act, will ... identified by Toretsky and his team a critical ...
... Texas, October 18, 2010 Estimates of the prevalence ... States population has non‐alcoholic fatty liver disease (NAFLD). NAFLD ... function tests in the United States, a trend related ... (NASH), the progressive form of NAFLD, can lead to ...
... Research exploring the progression of colon polyps to ... was among the clinical science presented at the 75th ... in San Antonio today. The Progression to Colorectal ... colon known as sessile serrated adenomas (SSA) are found ...
... are reimbursed by Medicaid for administering influenza shots may ... the conclusion of a study published online today in ... by a team of researchers at the University of ... three flu seasons and contends that the number of ...
Cached Medicine News:Health News:Egg allergy: Not a reason to avoid flu vaccine after all 2Health News:Egg allergy: Not a reason to avoid flu vaccine after all 3Health News:Young Kids Easily Trust What They're Told: Study 2Health News:$4.37 million NCI grant accelerates recent laboratory finding in Ewing's sarcoma 2Health News:$4.37 million NCI grant accelerates recent laboratory finding in Ewing's sarcoma 3Health News:Encouraging findings suggest new avenues for treating liver disease in overweight Americans 2Health News:Encouraging findings suggest new avenues for treating liver disease in overweight Americans 3Health News:Colonoscopy technique increases polyp detection in far reaches of right colon 2Health News:Medicaid reimbursement and childhood flu vaccination rates linked 2Health News:Medicaid reimbursement and childhood flu vaccination rates linked 3
... up to 10 inches/ 25 cm thinner than other ... Allegra X-22 Series is the space-saving multipurpose solution for ... / 46 cm wide • 11 Rotor Library • ... ways to Spin 1.5 mL & PCR+ Tubes: ...
... is up to 10 inches/ 25 cm thinner than ... the Allegra X-22 Series is the space-saving multipurpose solution ... inches / 46 cm wide • 11 Rotor Library ... different ways to Spin 1.5 mL & PCR+ Tubes: ...
... centrifuges offer high-volume versatility along with a ... them ideal for a wide variety of ... Four- or six-place sealed swinging bucket rotor, ... offered , Lare capacity (4 x 750 ...
... Multipurpose high performance centrifuge designed to accommodate ... devices is refrigerated for heat labile samples. ... include refrigerated capability with automatic quick cooling ... < 7 min, no maintenance brushless motor, ...
Medicine Products: